Kidney Injury in Multiple Myeloma; Predisposing Factors, Manifestations & Outcome, Single Center Experience
DOI:
https://doi.org/10.14738/bjhr.1303.2398Abstract
Introduction: Multiple Myeloma (MM) is third most common hematological malignancy. Renal impairment is observed in 25-75% patients with MM, could be due to disease itself or other unrelated causes, also its second most common cause of death after infection in MM patients. Purpose of this study is to compare clinical & lab parameters of multiple myeloma patients with & without kidney injury also to determine outcome of kidney injury. Results: Between 2017 to 2024, thirty-two patients were diagnosed with MM, their mean age was 61.62±12.05 years, and 78.12% were male. . Hypertension (n=11, 34.37%) & diabetes mellitus (n=7, 21.87%) were most common co morbid, and body aches/weakness (62.50%), fractures (17.64%) & anemia (17.64%) were common manifestations. Anemia, hypocalcemia, hypercalcemia & hypoalbuminemia was observed in 56.25%, 21.87%, 25% & 46.87% patients respectively. Kidney injury(KI) (Acute kidney injury or acute on chronic kidney disease) was observed in 68.75% patients, and mortality was 43.75%. MM patients with kidney injury (MM-KI) belonged to older age (63.77±11.15) group than MM patients with normal kidney functions (MM-NKF) (59.5±14.5 (p=0.255), their mean creatinine was 1.8(1.65) mg/dl, & proteinuria was 255.5(450.25) mg/day. Nine patients (40.90%) require renal replacement therapy in form of hemodialysis during course of treatment, and 18(81.81%) patients had full or partial recovery of renal functions. Mean hemoglobin & albumin was statistically significantly low in MM-KI group than MM-NKF, however fracture & anemia was more frequent among MM-NKF group, but statistically insignificant. Overall one, three & five-year survival rate for MM patients was 97%, 81% & 62% respectively. Conclusion: Our study showed that higher mortality was observed in MM patients with kidney injury. Early intervention of kidney injury predisposing factors may affect the renal & mortality outcome. This is one of few reported data on MM patients in UAE, we hope that further studies involving multicentric approach in MM patients could provide more detailed overview of kidney disease in these patients.
References
Medical Masterclass contributors; Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019 Jan;19(1):58-60. doi: 10.7861/clinmedicine.19-1-58
Anderson KC: Multiple myeloma: a clinical overview. Oncology (Williston Park). 2011, 15:3-9.
Rasch S, Lund T, Asmussen JT, Lerberg NA, Faebo LR, Østerheden AM, Abildgaard N: Multiple myeloma associated bone disease.Cancers. 2020, 12:2113. 10.3390/cancers12082113.
Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, Ma L, Liu X, Zhou F. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023 May 17;13(1):82. doi: 10.1038/s41408-023-00853-3.
Khan F, Farghaly M, Aljabban A, Zayed M, Subramanyam K, Chickballapur Ramachandrachar B. Disease burden, comorbidities, and treatment patterns of patients with multiple myeloma in Dubai: a retrospective analysis of the Dubai real-world claims database. Curr Med Res Opin. 2025 Aug;41(8):1407-1416. doi: 10.1080/03007995.2025.2560656.
Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA; Greek Myeloma Study Group. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007 Feb;48(2):337-41. doi: 10.1080/10428190601126602.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan;78(1):21-33. doi: 10.4065/78.1.21.
Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010 Dec 16;116(25):5501-6. doi: 10.1182/blood-2010-07-298760. Epub 2010 Sep 7.1.
Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1.
Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer. 2007 Dec 1;121(11):2512-6. doi: 10.1002/ijc.22968.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X
Mester B, Nieters A, Deeg E, Elsner G, Becker N, Seidler A. Occupation and malignant lymphoma: a population based case control study in Germany. Occup Environ Med. 2006 Jan;63(1):17-26. doi: 10.1136/oem.2005.020453.
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791. Scholar Publishing
Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013 Oct;42(10):684-8.
Stompór T, Zabłocki M, Pankrac K. Renal involvement in multiple myeloma. Pol Arch Med Wewn. 2012;122(9):443-8.
Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975 Jan;50(1):29-40.
Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998 Sep 28;158(17):1889-93. doi: 10.1001/archinte.158.17.1889.
Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994 Oct;53(4):207-12. doi: 10.1111/j.1600-0609.1994.tb00190.x.
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044.
Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon JM, Fermand JP, Touchard G, Bridoux F. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2016 Jan;31(1):64-72. doi: 10.1093/ndt/gfv283.
Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103.
Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, Psimenou E, Nikitas N, Terpos E, Dimopoulos MA. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma. 2011 Dec;52(12):2299-303. doi: 10.3109/10428194.2011.597906.
Munshi NC, Longo DL, Anderson KC. Plasma Cell Disorders; Harrison’s Principles of Internal Medicine. 17th ed., Ch. 106. McGraw Hill 2008. p. 703-7.
Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992 Apr 15;79(8):1987-94.
Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992 Oct 1;80(7):1639-47.
Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992 Dec;82(4):648-53. doi: 10.1111/j.1365-2141.1992.tb06939.x.
Cesar BN, Braga WMT, Hamerschlak N, Junior MSD. Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery. BMC Nephrol. 2024 Oct 11;25(1):344. doi: 10.1186/s12882-024-03717-5.
Motwani SS, Herlitz L, Monga D, Jhaveri KD, Lam AQ; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Scholar Publishing Paraproteinemias. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2260-2272. doi: 10.2215/CJN.02980316.
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005 Dec 20;23(36):9219-26. doi: 10.1200/JCO.2005.03.2086.
Chen X, Luo X, Zu Y, Issa HA, Li L, Ye H, Yang T, Hu J, Wei L. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. J Clin Lab Anal. 2020 Sep;34(9):e23416. doi: 10.1002/jcla.23416.
Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021 Feb 20;36(3):482-490. doi: 10.1093/ndt/gfz211.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 British Journal of Healthcare and Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
